Skip to main content
  • Tweet
  • Share on Facebook
  • Share on Google +1
  • Share via Email
  • Contact
  • Glossary
  • Subscribe
  • Search

PATH's Malaria Vaccine Initiative

Accelerating Malaria Vaccine Development

  • About us
    • Our leadership team
    • Donors
    • Contact us
  • Malaria and vaccines
    • Need for a vaccine
    • RTS,S
    • Malaria vaccine roadmap
    • Next-generation vaccines
      • Preventing transmission
      • Preventing infection
    • Vaccine development
      • Our research and development strategy
      • Life cycle of the malaria parasite
      • Preferred product characteristics
    • Evaluation technologies
    • Access
      • Global policy and regulatory pathways
        • Regulatory decisions and prequalifications
        • Policy
      • Preparing for malaria vaccine decisions
        • The decision-making framework tool for malaria vaccines
        • Decision-making framework
          • Economic analysis
          • Public health impact analysis
          • Sociocultural research
      • Financing
        • Gavi, the Vaccine Alliance
        • Other fincancing mechanisms
  • Projects
    • Search vaccine projects
    • Evaluation technology projects
    • MVI Portfolio
    • Past projects
  • Resources
    • Search all resources
    • Fact sheets
    • Journal articles
    • Presentations
    • Videos
    • Reports
  • News and events
    • Press releases
    • Perspectives
    • Malaria vaccine news
    • Events
  • Work with us
    • RFPs
    • Advocacy
      • Malaria Vaccine Advocacy Fellowship
      • Past advocacy fellows
      • Tools for advocates
    • Propose a project
  • About us
    • Our leadership team
    • Donors
    • Contact us
  • Malaria and vaccines
    • Need for a vaccine
    • RTS,S
    • Malaria vaccine roadmap
    • Next-generation vaccines
      • Preventing transmission
      • Preventing infection
    • Vaccine development
      • Our research and development strategy
      • Life cycle of the malaria parasite
      • Preferred product characteristics
    • Evaluation technologies
    • Access
      • Global policy and regulatory pathways
      • Preparing for malaria vaccine decisions
      • Financing
  • Projects
    • Search vaccine projects
    • Evaluation technology projects
    • MVI Portfolio
    • Past projects
  • Resources
    • Search all resources
    • Fact sheets
    • Journal articles
    • Presentations
    • Videos
    • Reports
  • News and events
    • Press releases
    • Perspectives
    • Malaria vaccine news
    • Events
  • Work with us
    • RFPs
    • Advocacy
      • Malaria Vaccine Advocacy Fellowship
      • Past advocacy fellows
      • Tools for advocates
    • Propose a project
  • Home
  • Home
A child sits with his mother

Two families reflect on their malaria vaccine journey

Catching up with the first children to receive the RTS,S malaria vaccine in Malawi, one year later.

Kenya strengthens fight against malaria with new vaccine

 The world's first malaria vaccine is now available in certain areas of Kenya, offering an additional way to protect young children from this disease, which is a top 10 cause of illness and death, and a leading killer of children under the age of five....

GSK, PATH, and Bharat Biotech sign product transfer agreement to help ensure long-term supply of RTS,S/AS01E malaria vaccine

Bharat Biotech will produce the antigen for RTS,S/AS01 following technology transfer. Read more

We’re ready to beat malaria. Are you?

Put your knowledge to the test with a three-question quiz. Ready to begin?

Home

  • MVI Portfolio

    We strategically use our resources to support and advance a range of vaccine approaches that target both humoral and cellular immunity. 
    Explore
  • Evaluation technology projects

    We partner to develop and optimize new assays and challenge models and support reference and service laboratories.
    Explore
  • RTS,S

    RTS,S/AS01 (RTS,S) is the world’s first malaria vaccine shown to provide partial protection against malaria in young children.
    Explore

Latest

GSK, PATH, and Bharat Biotech sign product transfer agreement to help ensure long-term supply of RTS,S/AS01E malaria vaccine
Press release
27 Jan 2021
Frequently Asked Questions (FAQs): Product Transfer for the RTS,S/AS01 Malaria Vaccine
Fact sheet
27 Jan 2021
Milestone study identifies immune markers that may help predict success of vaccination with RTS,S/AS01 malaria vaccine
Press release
22 Jul 2020
PATH receives new five-year contract from USAID for malaria vaccine research and development
Press release
7 Jul 2020
A child sits with his mother Two families reflect on their malaria vaccine journey
Feature
23 Apr 2020
PATH continues exciting partnership with the GHIT Fund to develop a next-generation malaria vaccine
Press release
3 Apr 2020
Characterization of two in vivo challenge models to measure functional activity of monoclonal antibodies to Plasmodium falciparum circumsporozoite protein
Journal article
17 Mar 2020
RTS,S Malaria Vaccine: 2019 Partnership Award Honoree
Video
4 Dec 2019
PATH and partners receive award for development of world’s first malaria vaccine
Press release
14 Nov 2019
RTS,S malaria vaccine frequently asked questions (FAQs)
Fact sheet
17 Sep 2019
The RTS,S malaria vaccine
Fact sheet
17 Sep 2019
Pictured here with his mother, Elian Koech was the first child to receive the vaccine in Kenya. Kenya joins Malawi and Ghana to roll out the world’s first malaria vaccine
Press release
13 Sep 2019
  • Need for a vaccine

    A vaccine could help to close the gap left by other malaria control interventions.
  • Malaria vaccine roadmap

    The roadmap outlines a path for accelerating the development of malaria vaccines.
  • RTS,S

    RTS,S/AS01 (RTS,S) is the world’s first malaria vaccine shown to provide partial protection against...
  • Next-generation vaccines

    The next generation of malaria vaccines would aim to reduce transmission of the parasite.

Twitter @MalariaVaccine

RT @PATHMalaria: Genomic sequencing in Zambia is helping shed light on recent increases in #COVID19 cases and geographic spread. R… https://t.co/MjP8PCGTX6
5 Mar 2021
RT @SciDevNet: Scientists have analysed genetic variations of 7,000 Plasmodium falciparum parasites from 28 countries, and curated… https://t.co/tftazpkLlU
3 Mar 2021
https://t.co/W3PQHVKYB2 via @pathtweets
15 Feb 2021
RT @womeninmalaria: Thrilled to announce the 1ST Women In Malaria conference to be held 22-24th March 2021 with an amazing line-up of s… https://t.co/Bm64s4JzJl
12 Feb 2021
RT @JHMRImalaria: Learning from COVID-19 to accelerate #malaria vaccine development. https://t.co/N22OQn9d7i
10 Feb 2021
RT @endmalaria: Today marks the start of the 34th @_AfricanUnion summit, with the theme of ‘Building the Africa we want’. Here our… https://t.co/5F5jNVSiue
9 Feb 2021
RT @PATHtweets: Today we are thrilled to announce with our partners @GSK and @BharatBiotech the product transfer agreement to help… https://t.co/vktn8t4wg7
4 Feb 2021
RT @BillGates: This has been a year unlike any other in our lifetimes. In our new Annual Letter, Melinda and I talk about how we c… https://t.co/3obA3hYggD
2 Feb 2021
GSK to move malaria vaccine production to India's Bharat Biotech https://t.co/GcwezRz8Hv
28 Jan 2021
GSK grants India's Bharat Biotech licensing rights to malaria vaccine https://t.co/vwpDZKdyZJ
27 Jan 2021
We are delighted to announce today with our partners @GSK and @BharatBiotech the product transfer agreement to hel… https://t.co/09mtd4LkgQ
27 Jan 2021
A Reproducible and Scalable Process for Manufacturing a Pfs48/45 Based Plasmodium falciparum Transmission-Blocking… https://t.co/bUxi9sBsSU
22 Jan 2021

PATH Washington DC

455 Massachusetts Avenue NW, Suite 1000

Washington, DC 20001 | USA 

Tel: 202.822.0033

Fax: 202.457.1466

Email: mvi_info [at] path.org

PATH Headquarters

2201 Westlake Avenue, Suite 200

Seattle, WA 98121 | USA 

Tel: 206.285.3500

Fax: 206.285.6619

Email: info [at] path.org

Website: www.path.org

Follow us

Mail
Twitter
  • Privacy policy
  • Copyright policy
  • Terms of use
© 2021 PATH
Website by Manta Ray Media